NCT02772289 - Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

March 31, 2019

Conditions

Cicatrix

Interventions

BIOLOGICAL

Mesenchyme Stem Cells low-dose group

Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.

BIOLOGICAL

Mesenchyme Stem Cells high-dose group

Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.

BIOLOGICAL

Placebo

Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.

Trial Locations (1)

528000

Maternal and Child Health Hospital of Foshan, Foshan

All Listed Sponsors

lead

Maternal and Child Health Hospital of Foshan

OTHER